Click Here to
News, Updates,
& More
Stay Up
to Date

Case Reports

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with a median age of approximately 65 years at diagnosis, and an increasing incidence with age.
Amany R. Keruakous, MD; Sarah A. Schmidt, PharmD; Marcus T. Autry, PharmD; Julia Ye, PharmD Candidate; Phoi Nguyen, PharmD Candidate; Silas Day
Targeting the human epidermal growth factor receptor (HER)2 protein has proved efficacy for the treatment of breast, gastric, and gastroesophageal cancers.
Anna Kempke, PharmD, BCOP, BCPS; Shawna Kraft, PharmD, BCOP; Mariana Castells, MD, PhD; Rajan Ravikumar, MD; Catherine Van Poznak, MD
In 2019, approximately 174,650 new cases of prostate cancer were reported, representing 9.9% of all new cancers in the United States.
Chemotherapy-induced nausea and vomiting (CINV) is estimated to affect more than 60% of patients with cancer, and has negative consequences for patients’ quality of life, treatment adherence, and outcomes.
Ampullary carcinoma is a rare type of tumor that arises from the ampulla of Vater, otherwise known as the hepatopancreatic ampulla.
Fulvestrant and palbociclib are each approved for the treatment of HR-positive metastatic breast cancer, and can also be used in combination. Cases of hepatotoxicity and elevated liver enzymes have been documented with each agent when used as monotherapy.
High-dose methotrexate is an integral component of treatment regimens for a variety of pediatric malignancies, including osteosarcoma, acute lymphoblastic leukemia, and non-Hodgkin lymphoma.
Nivolumab is now approved for every 4-week dosing. Nivolumab 480-mg dosing may have led to a more severe case of transaminitis than the every 2-week dosing in this patient with non–small-cell lung cancer, who had severe transaminitis 21 days after administration of the first dose. The steroid-refractory nature of this patient’s transaminitis, and the unclear current recommendations for infection prophylaxis, complicated the management of this patient’s autoimmune reaction.
Scleroderma is a condition in which chronic inflammation and immune effects in the tissue lead to fibrotic changes caused by excess collagen and potentially vascular damage in the skin.1,2 These immunologic changes lead to a hardening and thickening of various depths of the skin, which may have profound effects on a patient’s quality of life and requires complex medical management.
Paclitaxel is a taxane-derived antineoplastic agent that is often used for US Food and Drug Administration (FDA)-approved indications such as breast cancer, AIDS-related Kaposi sarcoma, ovarian cancer, and non–small-cell lung cancer (NSCLC).1 It is also widely used for a number of off-label indications, and it works by promoting the assembly of microtubules, further enhancing the inhibition of cellular replication. It is administered as an intravenous (IV) solution, and its dosage and duration of treatment vary based on the indication.1 Patients with high-risk breast cancer in the preoperative or the adjuvant setting can receive either dose-dense paclitaxel (ie, 175 mg/m2 every 2 weeks for 4 cycles) or weekly paclitaxel (ie, 80 mg/m2 weekly for 12 weeks). In breast cancer, paclitaxel can be administered after the use of an anthracycline, in combination with cyclophosphamide.
Page 1 of 2
Results 1 - 10 of 16